Annual EBITDA
-$81.31 M
-$28.14 M-52.93%
December 31, 2023
Summary
- As of February 8, 2025, AVTE annual EBITDA is -$81.31 million, with the most recent change of -$28.14 million (-52.93%) on December 31, 2023.
- During the last 3 years, AVTE annual EBITDA has fallen by -$72.42 million (-814.86%).
- AVTE annual EBITDA is now -2341.83% below its all-time high of -$3.33 million, reached on December 31, 2019.
Performance
AVTE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$17.19 M
+$8.95 M+34.22%
September 30, 2024
Summary
- As of February 8, 2025, AVTE quarterly EBITDA is -$17.19 million, with the most recent change of +$8.95 million (+34.22%) on September 30, 2024.
- Over the past year, AVTE quarterly EBITDA has increased by +$4.85 million (+21.99%).
- AVTE quarterly EBITDA is now -1129.76% below its all-time high of -$1.40 million, reached on March 1, 2020.
Performance
AVTE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$89.96 M
+$4.15 M+4.41%
September 30, 2024
Summary
- As of February 8, 2025, AVTE TTM EBITDA is -$89.96 million, with the most recent change of +$4.15 million (+4.41%) on September 30, 2024.
- Over the past year, AVTE TTM EBITDA has dropped by -$8.64 million (-10.63%).
- AVTE TTM EBITDA is now -6334.69% below its all-time high of -$1.40 million, reached on March 1, 2020.
Performance
AVTE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
AVTE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -52.9% | +22.0% | -10.6% |
| 3 y3 years | -814.9% | +22.0% | -10.6% |
| 5 y5 years | -2341.8% | +22.0% | -10.6% |
AVTE EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -253.4% | at low | -108.1% | +34.2% | -291.0% | +4.4% |
| 5 y | 5-year | -2341.8% | at low | -1129.8% | +34.2% | -6334.7% | +4.4% |
| alltime | all time | -2341.8% | at low | -1129.8% | +34.2% | -6334.7% | +4.4% |
Aerovate Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$17.19 M(-34.2%) | -$89.96 M(-4.4%) |
| Jun 2024 | - | -$26.14 M(+6.3%) | -$94.11 M(+6.6%) |
| Mar 2024 | - | -$24.59 M(+11.6%) | -$88.28 M(+8.6%) |
| Dec 2023 | -$81.31 M(+52.9%) | -$22.04 M(+3.3%) | -$81.31 M(+8.3%) |
| Sep 2023 | - | -$21.34 M(+5.1%) | -$75.11 M(+10.6%) |
| Jun 2023 | - | -$20.31 M(+15.3%) | -$67.90 M(+13.6%) |
| Mar 2023 | - | -$17.62 M(+11.3%) | -$59.78 M(+12.4%) |
| Dec 2022 | -$53.17 M | -$15.83 M(+12.0%) | -$53.17 M(+16.6%) |
| Sep 2022 | - | -$14.13 M(+15.9%) | -$45.60 M(+21.1%) |
| Jun 2022 | - | -$12.20 M(+10.8%) | -$37.66 M(+20.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$11.01 M(+33.3%) | -$31.24 M(+35.8%) |
| Dec 2021 | -$23.01 M(+158.9%) | -$8.26 M(+33.3%) | -$23.01 M(+25.0%) |
| Sep 2021 | - | -$6.20 M(+7.4%) | -$18.41 M(+27.4%) |
| Jun 2021 | - | -$5.77 M(+107.8%) | -$14.46 M(+40.2%) |
| Mar 2021 | - | -$2.78 M(-24.1%) | -$10.31 M(+15.5%) |
| Dec 2020 | -$8.89 M(+166.9%) | -$3.66 M(+63.3%) | -$8.93 M(+69.5%) |
| Sep 2020 | - | -$2.24 M(+38.0%) | -$5.27 M(+74.2%) |
| Jun 2020 | - | -$1.63 M(+16.2%) | -$3.02 M(+116.2%) |
| Mar 2020 | - | -$1.40 M | -$1.40 M |
| Dec 2019 | -$3.33 M | - | - |
FAQ
- What is Aerovate Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Aerovate Therapeutics?
- What is Aerovate Therapeutics annual EBITDA year-on-year change?
- What is Aerovate Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Aerovate Therapeutics?
- What is Aerovate Therapeutics quarterly EBITDA year-on-year change?
- What is Aerovate Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Aerovate Therapeutics?
- What is Aerovate Therapeutics TTM EBITDA year-on-year change?
What is Aerovate Therapeutics annual EBITDA?
The current annual EBITDA of AVTE is -$81.31 M
What is the all time high annual EBITDA for Aerovate Therapeutics?
Aerovate Therapeutics all-time high annual EBITDA is -$3.33 M
What is Aerovate Therapeutics annual EBITDA year-on-year change?
Over the past year, AVTE annual EBITDA has changed by -$28.14 M (-52.93%)
What is Aerovate Therapeutics quarterly EBITDA?
The current quarterly EBITDA of AVTE is -$17.19 M
What is the all time high quarterly EBITDA for Aerovate Therapeutics?
Aerovate Therapeutics all-time high quarterly EBITDA is -$1.40 M
What is Aerovate Therapeutics quarterly EBITDA year-on-year change?
Over the past year, AVTE quarterly EBITDA has changed by +$4.85 M (+21.99%)
What is Aerovate Therapeutics TTM EBITDA?
The current TTM EBITDA of AVTE is -$89.96 M
What is the all time high TTM EBITDA for Aerovate Therapeutics?
Aerovate Therapeutics all-time high TTM EBITDA is -$1.40 M
What is Aerovate Therapeutics TTM EBITDA year-on-year change?
Over the past year, AVTE TTM EBITDA has changed by -$8.64 M (-10.63%)